JP2004510750A5 - - Google Patents

Download PDF

Info

Publication number
JP2004510750A5
JP2004510750A5 JP2002532258A JP2002532258A JP2004510750A5 JP 2004510750 A5 JP2004510750 A5 JP 2004510750A5 JP 2002532258 A JP2002532258 A JP 2002532258A JP 2002532258 A JP2002532258 A JP 2002532258A JP 2004510750 A5 JP2004510750 A5 JP 2004510750A5
Authority
JP
Japan
Prior art keywords
agonist
ppardelta
activator
ppar delta
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002532258A
Other languages
English (en)
Japanese (ja)
Other versions
JP4106263B2 (ja
JP2004510750A (ja
Filing date
Publication date
Priority claimed from GBGB0024361.8A external-priority patent/GB0024361D0/en
Application filed filed Critical
Publication of JP2004510750A publication Critical patent/JP2004510750A/ja
Publication of JP2004510750A5 publication Critical patent/JP2004510750A5/ja
Application granted granted Critical
Publication of JP4106263B2 publication Critical patent/JP4106263B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002532258A 2000-10-05 2001-10-01 炎症性の状態の治療のためのpparデルタ活性化因子の使用 Expired - Fee Related JP4106263B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024361.8A GB0024361D0 (en) 2000-10-05 2000-10-05 Medicaments
PCT/GB2001/004373 WO2002028434A2 (en) 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions

Publications (3)

Publication Number Publication Date
JP2004510750A JP2004510750A (ja) 2004-04-08
JP2004510750A5 true JP2004510750A5 (https=) 2005-12-22
JP4106263B2 JP4106263B2 (ja) 2008-06-25

Family

ID=9900709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002532258A Expired - Fee Related JP4106263B2 (ja) 2000-10-05 2001-10-01 炎症性の状態の治療のためのpparデルタ活性化因子の使用

Country Status (9)

Country Link
US (1) US7084161B2 (https=)
EP (1) EP1324774B1 (https=)
JP (1) JP4106263B2 (https=)
AT (1) ATE318615T1 (https=)
AU (1) AU2001292046A1 (https=)
DE (1) DE60117584T2 (https=)
ES (1) ES2259675T3 (https=)
GB (1) GB0024361D0 (https=)
WO (1) WO2002028434A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
CA2449247A1 (en) * 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
EP1435946B8 (en) 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
FR2836829B1 (fr) * 2002-03-11 2005-11-25 Bio Merieux Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
WO2005097098A2 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. Use of ppr delta agonists for treating demyelinating diseases
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
WO2006020830A2 (en) 2004-08-12 2006-02-23 Amgen Inc. Bisaryl-sulfonamides
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
US8802705B2 (en) * 2007-05-21 2014-08-12 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing PPAR delta agonist
AU2010282399A1 (en) * 2009-08-14 2012-03-01 Cerenis Therapeutics Holding S.A. Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
KR102038866B1 (ko) * 2012-12-24 2019-10-31 서울대학교산학협력단 PPARδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU8355998A (en) * 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds

Similar Documents

Publication Publication Date Title
JP2004510750A5 (https=)
JP2006526590A5 (https=)
JP2002543065A5 (https=)
JP2008543854A5 (https=)
JP2004535466A5 (https=)
JP2002161074A5 (https=)
JP2009536178A5 (https=)
KR960041168A (ko) 베타-아드레날린 효능성 작용물질
JP2006517939A5 (https=)
JP2004516314A5 (https=)
JP2005511547A5 (https=)
CN1633285A (zh) 组合物
CA2436846A1 (en) Thioether substituted imidazoquinolines
JP2018135343A5 (https=)
CN1284877A (zh) 胃保护性奥美拉唑微粒、其制备方法及药物制剂
JP2009541387A5 (https=)
JP2005527576A5 (https=)
JP2015508068A5 (https=)
JP2004510749A5 (https=)
CN1210027C (zh) 治疗溃疡的药物组合物及其应用
JP2005517677A5 (https=)
EP1612208A3 (en) N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation
JP2004532828A5 (https=)
JP2007515467A5 (https=)
JP2005502636A5 (https=)